Clinically significant ILD

Prior treatment with cellular therapy (CAR-T) or gene therapy product directed at any target

History of allogeneic or autologous stem cell transplant

Evidence of active hepatitis B or hepatitis C infection

Positive serology for HIV

Primary immunodeficiency

History of splenectomy

History of stroke, seizure, dementia, Parkinson's disease, coordination movement disorder, cerebellar diseases, psychosis, paresis, aphasia, and any other neurologic disorder investigator considers would increase the risk for the subject

Impaired cardiac function or clinically significant cardiac disease

Previous or concurrent malignancy with the following exceptions:

1. Adequately treated basal cell or squamous cell carcinoma (adequate wound healing is required prior to screening)
2. In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to screening
3. A primary malignancy which has been completely resected, or treated, and is in complete remission for at least 5 years prior to screening